Nanoviricides, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
NanoViricides, Inc. reports progress in broad-spectrum antiviral drug NV-387's clinical development, including Phase Ia/Ib completion, but faces significant financial constraints and a going concern doubt.
AMEX
NanoViricides, a clinical-stage company, released its 10-K filing, detailing progress in its nanoviricide drug development programs, particularly NV-387, and its financial status.